Qiagen N.V. (QGEN): Depreciation & Amortization
$193.75M
Year ended 2025-12-31
-2.4%
3-year compound annual growth
-1.1%
5-year compound annual growth
+0.1%
10-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $193.75M | -4.7% | 2026-03-20, From 2025-01-01 |
| 2024-12-31 | $203.27M | -1.0% | 2026-03-20, From 2024-01-01 |
| 2023-12-31 | $205.34M | -1.5% | 2026-03-20, From 2023-01-01 |
| 2022-12-31 | $208.40M | -3.0% | 2025-03-31, From 2022-01-01 |
| 2021-12-31 | $214.93M | +4.8% | 2024-03-11, From 2021-01-01 |
| 2020-12-31 | $205.01M | -11.4% | 2023-03-13, From 2020-01-01 |
| 2019-12-31 | $231.46M | +12.1% | 2022-03-14, From 2019-01-01 |
| 2018-12-31 | $206.44M | -4.6% | 2021-03-05, From 2018-01-01 |
| 2017-12-31 | $216.45M | +1.6% | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $213.06M | +11.3% | 2019-03-06, From 2016-01-01 |
| 2015-12-31 | $191.47M | -4.6% | 2018-03-06, From 2015-01-01 |
| 2014-12-31 | $200.78M | +0.7% | 2017-03-06, From 2014-01-01 |
| 2013-12-31 | $199.35M | +0.7% | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | $197.89M | +18.2% | 2015-03-02, From 2012-01-01 |
| 2011-12-31 | $167.38M | +17.2% | 2014-03-03, From 2011-01-01 |
| 2010-12-31 | $142.78M | +193.9% | 2013-03-04, From 2010-01-01 |
| 2009-12-31 | $48.58M | +14.0% | 2012-03-27, From 2009-01-01 |
| 2008-12-31 | $42.62M | n/a | 2011-03-21, From 2008-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Qiagen N.V. (QGEN) | 2025-12-31 | $193.75M | -4.7% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $211.00M | +14.1% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $29.05M | +0.9% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $11.39M | +11.0% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $97.36M | -11.4% |
| Novavax Inc (NVAX) | 2025-12-31 | $27.61M | -43.1% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $1.39M | +11.5% |
| Repligen Corp (RGEN) | 2025-12-31 | $78.75M | +13.0% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $8.10M | +0.6% |
Compare QGEN, MRNA, EXEL, HALO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗